The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; Debiopharm Group; Incyte; Klus Pharma; Pieris Pharmaceuticals; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Angela Lamarca
Consulting or Advisory Role - Eisai; Ipsen; Nutricia; Nutricia (I); QED Therapeutics; Roche
Speakers' Bureau - Advanced Accelerator Applications; Incyte; Ipsen; Ipsen (I); Merck; Novartis (I); Pfizer; Pfizer (I)
Research Funding - Ipsen; Ipsen (I)
Travel, Accommodations, Expenses - Abbott Nutrition; Advanced Accelerator Applications; Bayer; Celgene; Delcath Systems; Ipsen; Ipsen (I); Mylan; NanoString Technologies (I); Novartis; Pfizer; Sirtex Medical
 
John H. Strickler
Consulting or Advisory Role - Amgen; Bayer; Chengdu Kanghong Biotech; Genentech/Roche; OncoMed; Proteus Digital Health; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Curegenix; Exelixis (Inst); Gilead Sciences (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); MedImmune (Inst); Nektar (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Michael Cecchini
Honoraria - AstraZeneca; Eisai
Travel, Accommodations, Expenses - AstraZeneca; Eisai
 
Daniel H. Ahn
Consulting or Advisory Role - Astellas Pharma; Cardinal Health; Celltrion (I); Eisai; Exelixis; Lexicon
 
Islam Baiev
No Relationships to Disclose
 
Alice Boileve
No Relationships to Disclose
 
Melodie Tazdait
No Relationships to Disclose
 
Lindsay Marie Hannan
No Relationships to Disclose
 
Jingquan Jia
No Relationships to Disclose
 
Hetal Desai Marble
No Relationships to Disclose
 
Afsaneh Barzi
Consulting or Advisory Role - Bayer Technology System; bioTheranostics; Merrion
Research Funding - Bayer (Inst); Merck (Inst)
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Celgene; Halozyme; Incyte; Ipsen; Klus Pharma; Newlink Genetics; QED Therapeutics
Research Funding - Agios (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); FibroGen (Inst); Halozyme (Inst); Incyte (Inst); Ipsen (Inst); MedImmune (Inst); Rafael Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ASCO; FibroGen; FibroGen
 
Jochen K Lennerz
No Relationships to Disclose
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche; Gilead Sciences; Merck (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly; NCCN; Pfizer; Regeneron; Sirtex Medical; Taiho Pharmaceutical
Research Funding - NCCN; NCI; Oncolytics
Other Relationship - Exelixis; Polaris
 
Milind M. Javle
Consulting or Advisory Role - incyte; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Nataliya Volodymyrivna Uboha
Consulting or Advisory Role - AstraZeneca; EMD Serono; Flatiron Health; Gerson Lehrman Group; Incyte; ipsen; LEK; Lilly; Lilly; M3; Taiho Pharmaceutical
Research Funding - EMD Serono (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)
 
William P. Harris
No Relationships to Disclose
 
Antoine Hollebecque
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor